CCELNYSEServices-Misc Health & Allied Services, NECFiscal year ends November 30
CRYO CELL INTERNATIONAL INC
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 9, 2026
$4.65+0.23 (+5.20%)
Close on Oct 19, 2026
- Market cap
- $37.50M
- P/E (TTM)
- –
- Dividend yield
- –
CRYO CELL INTERNATIONAL INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member] | $31.38M | $31.55M | $30.80M | $29.77M | $28.40M | $30.18M | $30.99M | $28.82M | $24.94M | – | 99.4% | -0.5% |
| Public Cord Blood Banking [Member] | $129.51K | $366.67K | $481.15K | $461.63K | $376.10K | $726.55K | $652.20K | $296.30K | – | – | 0.4% | -64.7% |
| PrepaCyte CB [Member] | $54.10K | $67.88K | $66.46K | $104.00K | $111.40K | $244.19K | $172.40K | $104.32K | $442.19K | – | 0.2% | -20.3% |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member] | $5.41M | $4.13M | -$7.91M | $5.19M | $6.36M | $9.93M | $8.15M | $5.62M | $5.07M | – | +31.0% |
| PrepaCyte CB [Member] | $14.21K | -$4.98K | $3.19K | -$24.49K | -$70.34K | $60.50K | -$113.35K | -$101.33K | -$61.00K | – | -385.5% |
| Public Cord Blood Banking [Member] | -$4.94M | -$646.54K | -$4.40M | -$1.14M | -$2.27M | -$2.33M | -$2.98M | -$329.76K | – | – | +664.6% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Processing and Storage Fees [Member] | $31.38M | $31.55M | $30.80M | $29.77M | $28.40M | $29.55M | $29.99M | $27.82M | $23.94M | – | 99.4% | -0.5% |
| Public Banking Revenue [Member] | $129.51K | $366.67K | $481.15K | $461.63K | $376.10K | $726.55K | $652.20K | $296.30K | – | – | 0.4% | -64.7% |
| Product Revenue [Member] | $54.10K | $67.88K | $66.46K | $104.00K | $111.40K | $244.19K | $172.40K | $104.32K | $442.19K | – | 0.2% | -20.3% |
| Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member] | – | – | – | – | – | – | – | – | $24.94M | $22.78M | – | – |
| PrepaCyte CB [Member] | – | – | – | – | – | – | – | – | $442.19K | $350.13K | – | – |
| Licensee and Royalty Income [Member] | – | – | – | – | – | $629.70K | $1.00M | $1.00M | $1.00M | – | – | – |
| Processing and Storage Royalties [Member] | – | – | – | – | $0 | $629.70K | $1.00M | $1.00M | $1.00M | – | – | – |
| Product Revenue [Member] | – | – | – | – | – | – | $172.40K | $104.32K | – | – | – | – |
| Public Banking Revenue [Member] | – | – | – | – | – | – | $652.20K | $296.30K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Cryo Cell International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.